CIMAvax EGF clinical trials
How each study uses CIMAvax EGF is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CIMAvax EGF studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2021 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 3
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test CIMAvax EGF.
- Nov 2026CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck CancerPhase 1/2 · Roswell Park Cancer Institute
Studies
Open first, then newest update. How each study uses CIMAvax EGF is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung CancerNot yet recruitingPhase 2Roswell Park Cancer InstituteNCT07543172Written as Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
- CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck CancerActive, not recruitingPhase 1/2Roswell Park Cancer InstituteNCT02955290Written as Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
- A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or RecurrenceCompletedEarly Phase 1Roswell Park Cancer InstituteNCT04298606Written as Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Given beside what is tested · 1 — CIMAvax EGF is usual care or a partner of the new treatment
Codes
What other systems call CIMAvax EGF · ClinicalTrials.gg INT005645
- MeSH (NLM) C550107CIMAvax EGFOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C550107 | CIMAvax EGF | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.